

# Targeted Discovery of Polycyclic Tetramate Macrolactams from an Environmental *Streptomyces* Strain


Shugeng Cao, Joshua A. V. Blodgett, and Jon Clardy\*

Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, 240 Longwood Avenue, Boston, Massachusetts 02115, United States

jon\_clardy@hms.harvard.edu

Received August 24, 2010

## ABSTRACT




A targeted polymerase chain reaction (PCR)-based screening approach was used to identify candidate polycyclic tetramate macrolactam (PTM) biosynthetic gene clusters in environmental *Streptomyces* isolates. Isolation and characterization of the small molecules produced by one of the strains confirmed the production of two new PTMs (clifednamides A, 4, and B, 5) and, more generally, the utility of using a targeted approach for the discovery of new members of this interesting class.

Ikarugamycin (**1**), dihydromaltophilin (**2**), and frontalamide A (**3**) comprise the founding, the most widely encountered, and the most recently discovered members of a related group of polycyclic tetramate macrolactams (PTMs) (Figure 1).<sup>1</sup> As the name suggests, this family of structurally complex and biologically active small molecules shares a macrocyclic lactam ring with an embedded tetramic acid ring along with a variable set of stereochemically rich carbocyclic rings. Ikarugamycin (**1**) has a 5–6–5 set of carbocyclic rings, but all other well-characterized PTMs have 5–5–6<sup>1b,c,2</sup> or 5–5<sup>3</sup> ring arrangements. Ikarugamycin (**1**) was originally reported in 1972 as an antiprotozoal agent,<sup>4</sup> and subsequent studies identified other family members in a desultory fashion.

(1) (a) Ito, S.; Hirata, Y. *Bull. Chem. Soc.* **1977**, *50*, 1813–1820. (b) Graupner, P. R.; Thornburgh, S.; Mathieson, J. T.; Chapin, E. L.; Kemmitt, G. M.; Brown, J. M.; Snipes, C. E. *J. Antibiot.* **1997**, *50*, 1014–1019. (c) Yu, F.; Zañeta-Rivera, K.; Zhu, X.; Huffman, J.; Millet, J. C.; Harris, S. D.; Yuen, G.; Li, X. C.; Du, L. *Antimicrob. Agents Chemother.* **2007**, *51*, 64–72. (d) Blodgett, J. A. V.; Oh, D. C.; Cao, S.; Currie, C. R.; Kolter, R.; Clardy, J. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 11692–11697.

(2) (a) Jakobi, M.; Winkelmann, G.; Kaiser, D.; Kempler, C.; Jung, G.; Berg, G.; Bahl, H. *J. Antibiot.* **1996**, *49*, 1101–1104. (b) Gunasekera, S. P.; Gunasekera, M.; McCarthy, P. *J. Org. Chem.* **1991**, *56*, 4830–4833.



**Figure 1.** Structures of compounds **1–5**. Note the rings A–E of ikarugamycin (**1**) are identical to those of the clifednamides (**4** and **5**).

Bacteria from diverse genera—*Streptomyces*, *Alteromonas*, *Stenotrophomonas*, and *Lysobacter*—produce PTMs.<sup>1–4</sup>

Many PTMs display antifungal activity, and a dihydro-maltophilin (**2**) producer (*Lysobacter enzymogenes* C3) has

been widely studied as a biocontrol agent for fungal infestations of agricultural crops.<sup>5</sup> In addition to the anti-protozoal and antifungal activities of PTMs, a recent study using expression-based pathway signature analysis identified ikarugamycin (**1**) and related compounds as “promising leads” for anticancer therapeutics.<sup>6</sup>

The recent identification of the frontalamide (**3**) biosynthetic locus enabled systematic searches for similar loci.<sup>1d</sup> Analyses of sequenced bacterial genomes revealed surprisingly large numbers of PTM biosynthetic loci, particularly within the *Streptomyces* genus. Strikingly, almost none of the identified bacteria were previously recognized as PTM producers. Further, a polymerase chain reaction (PCR)-based screen to detect PTM biosynthetic loci was used to probe environmental isolates, leading to numerous isolates harboring putative PTM clusters. Together these studies suggested that a targeted approach to PTM discovery would lead to new family members with potentially valuable properties. This communication outlines the implementation of such a PCR-guided search strategy to discover two new PTMs (**4** and **5**) with the unusual 5–6–5 set of carbocyclic rings found in **1**. These results corroborate previous sequence-driven PTM studies and illustrate the general utility of a targeted strategy to specifically discover new PTMs.

*Streptomyces* sp. JV178 produced putative PTM compounds (HPLC retention time, UV, and MS) after growth for five to six days at 30 °C on ISP4 agar. A crude extract of the culture plates was prepared by soaking the agar, with adhering mycelia intact, in ethyl acetate. After removing the solvent under vacuum, the dry crude material was dissolved in methanol before C-18 SPE treatment. Eluates containing **4** and **5** were separated by C-18 HPLC to afford the pure compounds, which we have named the clifednamides A and B.

Clifednamides A (**4**) and B (**5**) were obtained as colorless powders. Initial LC/MS analyses indicated that **4** had a molecular weight of 492 Da and a strong UV absorption at 327 nm. Compound **5** showed a similar UV absorption but a molecular weight of 508. The hydrocarbon skeletons of **4** and **5** were characterized with 1D (<sup>1</sup>H, <sup>13</sup>C) and 2D NMR methods.

The molecular formula of **4** was established as C<sub>29</sub>H<sub>36</sub>N<sub>2</sub>O<sub>5</sub> by high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). The <sup>1</sup>H NMR and HSQC spectra of **4** in 90% pyridine-*d*<sub>5</sub>/CD<sub>3</sub>OD showed the presence of six olefinic protons ( $\delta_{\text{H}}$  5.75, br d,  $J = 9.6$  Hz; 5.87, br d,  $J = 9.6$  Hz; 6.06, td,  $J = 11.1, 2.4$  Hz; 6.32, d,  $J = 11.1$  Hz; 6.86, dd,  $J = 15.6, 10.2$  Hz; 8.05, d,  $J = 15.6$  Hz), nine methine, six methylenes, and two methyl groups ( $\delta_{\text{H}}$  2.21, s; 0.88 d,  $J = 7.2$  Hz), and the <sup>13</sup>C NMR spectrum exhibited 29 signals,

including four carbonyls ( $\delta_{\text{C}}$  167.6, 174.3, 178.0, 209.9), four double bonds ( $\delta_{\text{C}}$  103.2, 124.0, 125.8, 129.7, 130.5, 139.9, 147.5, 197.6), and 17 sp<sup>3</sup> carbons from  $\delta_{\text{C}}$  19.3 to 61.4 ppm. In the COSY spectrum of **4**, three coupling systems from H-23 ( $\delta_{\text{H}}$  4.05, m) to H<sub>2</sub>-27 ( $\delta_{\text{H}}$  3.91, m; 2.85, m) through H<sub>2</sub>-25 ( $\delta_{\text{H}}$  2.24, m; 2.06, m) and H<sub>2</sub>-26 ( $\delta_{\text{H}}$  1.82, m; 1.60, m), from H-2 ( $\delta_{\text{H}}$  6.32, d,  $J = 11.1$  Hz) to H-5 ( $\delta_{\text{H}}$  1.49, m) through H-3 ( $\delta_{\text{H}}$  6.06, td,  $J = 11.1, 2.4$  Hz) and H-4 ( $\delta_{\text{H}}$  4.05, m; 2.60, m), and from H-18 ( $\delta_{\text{H}}$  8.05, d,  $J = 15.6$  Hz) to H-16 ( $\delta_{\text{H}}$  2.45, m) through H-17 ( $\delta_{\text{H}}$  6.86, dd,  $J = 15.6, 10.2$  Hz) were clearly demonstrated. The HMBC correlations from H-2, H-3, and H<sub>2</sub>-27 to C-1 ( $\delta_{\text{C}}$  167.6), from H-18 to C-19 ( $\delta_{\text{C}}$  174.3), C-20 ( $\delta_{\text{C}}$  103.2), and from H-23 to C-20, C-21 ( $\delta_{\text{C}}$  178.0), C-24 ( $\delta_{\text{C}}$  197.6), C-25 ( $\delta_{\text{C}}$  28.3), and C-26 ( $\delta_{\text{C}}$  22.3) established rings D and E of compound **4** to be a macrolactam with a tetramic acid unit as shown. The following key HMBC correlations were also observed: H-6 ( $\delta_{\text{H}}$  2.50, m) to C-8 ( $\delta_{\text{C}}$  130.5) and C-13 ( $\delta_{\text{C}}$  48.2); H-9 ( $\delta_{\text{H}}$  2.50, m) to C-7 ( $\delta_{\text{C}}$  129.7) and C-14 ( $\delta_{\text{C}}$  41.8); H<sub>3</sub>-30 ( $\delta_{\text{H}}$  2.21, s) to C-10 ( $\delta_{\text{C}}$  59.4) and C-29 ( $\delta_{\text{C}}$  209.9); H<sub>3</sub>-31 ( $\delta_{\text{H}}$  0.88 d,  $J = 7.2$  Hz) to C-10, C-11 ( $\delta_{\text{C}}$  34.2), and C-12 ( $\delta_{\text{C}}$  39.3); H-16 ( $\delta_{\text{H}}$  2.45, m) to C-6 ( $\delta_{\text{C}}$  43.2) and C-14 ( $\delta_{\text{C}}$  41.8). On the basis of these HMBC correlations, together with both COSY and TOCSY information, rings A–C of **4** were determined as a 5–6–5 tricyclic unit. In the ROESY spectrum of **4**, correlations between H-14 and H-6/H-9, H-10 and H-13, H<sub>3</sub>-31 and H-9, and H-16 and H-6/H-14 indicated *trans*–*cis*–*trans* A/B–B/C–C/D ring fusions. Hence the structure of **4** (clifednamide A) was determined as shown.

The molecular formula for clifednamide B (**5**) was determined as C<sub>29</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub> by HR-ESI-MS and <sup>13</sup>C NMR spectroscopy. The <sup>1</sup>H and <sup>13</sup>C NMR signals indicated rings A–E of **5** were very similar to those of **1** and **4**. The only observed difference between **4** and **5** was at the C-25-position, and the chemical shifts ( $\delta_{\text{H}}$  4.94, m;  $\delta_{\text{C}}$  73.1) of this position in **5** indicated an oxygenated methine. Given the likelihood that PTMs incorporate L-ornithine during their biosynthesis, H-23, which was originally the  $\alpha$ -proton of L-ornithine, should have a  $\beta$ -orientation. Molecular modeling (Chem3D-Ultra 9.0 MM2) predicted a dihedral angle of 78° ( $J = \sim 0.1$  Hz) for an  $\alpha$ -oriented H-25 (H-23–C-23–C-25–H-25) compared to 38° ( $J = \sim 5.0$  Hz) for a  $\beta$ -oriented H-25. H-23 ( $\delta_{\text{H}}$  4.74) appeared as a broad singlet, indicating that the dihedral angle must be close to 78°, that the 25-OH had a  $\beta$ -orientation, and that the structure of clifednamide B (**5**) is as shown.


On the basis of the structure of **1**, Ito and Hirata proposed that its biosynthesis involved coupling three fragments: one derived from ornithine and two 12-carbon chains derived from six acetate units<sup>1a</sup>—what today would be described as a hybrid PKS–NRPS pathway. The authors also proposed that the 5–6–5 ring system of **1** could, in principle, be formed by two aldol condensations and a formal Diels–Alder reaction (Figure 2) between appropriately functionalized PKS chains. By extension, the same might apply to the clifednamides. The later discovered and more common PTMs containing 5–5–6 and 5–5 systems obviously require different ring-forming reactions.

(3) (a) Bae, M. A.; Yamada, K.; Uemura, D.; Seu, J. H.; Kim, Y. H. *J. Microbiol. Biotechnol.* **1998**, *8*, 455–460. (b) Shigemori, H.; Bae, M. A.; Yazawa, K.; Sasaki, T.; Kobayashi, J. *J. Org. Chem.* **1992**, *57*, 4317–4320. (c) Kanazawa, S.; Fusetani, N.; Matsunaga, S. *Tetrahedron Lett.* **1993**, *34*, 1065–1068.

(4) Jomon, K.; Kuroda, Y.; Ajisaka, M.; Sakai, H. *J. Antibiot.* **1972**, *25*, 271–280.


(5) Li, S.; Jochum, C. C.; Yu, F.; Zaleta-Rivera, K.; Du, L.; Harris, S. D.; Yuen, G. Y. *Phytopathology* **2008**, *98*, 695–701.

(6) Tenenbaum, J. D.; Walker, M. G.; Utz, P. J.; Butte, A. J. *BMC Med. Genomics* **2008**, *1*, 51.



**Figure 2.** Hypothetical pathway<sup>1a</sup> leading to the production of **4** and **5**.

Identifying conserved PTM loci in sequenced bacterial genomes and environmental isolates underscores the pathway's evolutionary success. As a result, we undertook the targeted discovery of what are likely the many additional small molecules made by PTM pathways to explore their chemical diversity, biological potential, and ultimately, the basis of the pathway's high prevalence. The PTM cluster screen detects a small, but highly conserved (~800 bp in JV178) region common to all PTM loci identified thus far, with PCR primers annealing to portions of two conserved biosynthetic genes (Figure 3).<sup>1d</sup> One, *ftdA*, encodes a hydroxylase, and the other, *ftdB*, encodes a putative iterative hybrid PKS–NRPS synthetase. On the basis of the biosynthesis of **3**, it is likely that the JV178 FtdA homologue installs the hydroxyl at C-25 in **5**, and the FtdB hybrid PKS–NRPS forms the mixed polyketide/peptide backbone common to **4** and **5**.



**Figure 3.** PTM biosynthetic locus for compound **3**, consisting of genes *ftdA*–*ftdF*.<sup>1d</sup> PCR priming sites F1 and R1/R2 used to detect PTM clusters are shown for clarity. Primers not shown to scale.

The molecular diversity of the family therefore almost certainly lies in the pathway's other genes, those that code for enzymes to direct the multiple links between the two PKS-derived chains or perform tailoring reactions. Currently we know little about the reactions carried out by these genes, and a more detailed understanding will require connecting fully sequenced pathways with the small molecules they produce. Since nearly 50% of sequenced *Streptomyces* genomes contain apparent PTM biosynthetic loci,<sup>1d</sup> there are plenty of opportunities.

**Acknowledgment.** This project was supported by NIH GM086258 (JC), Harvard NERCE AI057159 (JC), CA024487 (JC), and a Harvard Microbial Sciences Initiative Postdoctoral Fellowship to JB.

**Supporting Information Available:** Experimental methods, NMR spectra, data tables, and supporting chemical data for clifednamides A and B (**4** and **5**). This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL1020064